Combination chemotherapy for spontaneous AKR lymphoma.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001681:Biological Assay; D002330:Carmustine / Q000627:therapeutic use; D003510:Cyclohexanes / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D008806:Mice, Inbred AKR; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000401:mortality; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D009929:Organ Size; D010169:Palmitic Acids / Q000627:therapeutic use; D011241:Prednisone / Q000494:pharmacology / Q000627:therapeutic use; D012075:Remission, Spontaneous; D012376:Rodent Diseases / Q000188:drug therapy; D013154:Spleen / Q000473:pathology; D013163:Splenomegaly / Q000473:pathology; D013950:Thymus Gland / Q000473:pathology; D013997:Time Factors; D014750:Vincristine / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003510:Cyclohexanes; D009607:Nitrosourea Compounds; D010169:Palmitic Acids; D003561:Cytarabine; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002330:Carmustine; D011241:Prednisone; D008727:Methotrexate